Dr. Edward J. Pearson, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Texas A & M University System, Hsc, College of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 629
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Texas A & M University System, Hsc, College of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license P9241 (first issued 2014; active) -
Internal Medicine Physician
TX license P9241 (first issued 2014; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
- Baylor Scott & White Medical Center- Waxahachie Waxahachie, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 629
- Services billed
- 91,473
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14,980 | 13 |
| Injection, pembrolizumab, 1 mg | 7,400 | 28 |
| Injection, fosaprepitant, 1 mg | 5,400 | 32 |
| Injection, paclitaxel, 1 mg | 5,322 | 32 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,981 | 45 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,004 | 83 |
| Blood test, comprehensive group of blood chemicals | 964 | 300 |
| Lactate dehydrogenase (enzyme) level | 939 | 301 |
| Insertion of needle into vein for collection of blood sample | 916 | 264 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 890 | 280 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Dallas, TX | 159 |
| Acyclovir Other prescribers in Dallas, TX | 97 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Dallas, TX | 92 |
| Xarelto (rivaroxaban) Other prescribers in Dallas, TX | 78 |
| Dexamethasone Other prescribers in Dallas, TX | 59 |
| Ninlaro (ixazomib citrate) | 51 |
| Venclexta (venetoclax) | 45 |
| Jakafi (ruxolitinib phosphate) | 42 |
| Prednisone Other prescribers in Dallas, TX | 40 |
| Revlimid (lenalidomide) | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 182 payments worth $180,764 in total to this clinician.
| Genzyme Corporation | $40,413 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $22,315 |
| Blueprint Medicines Corporation | $20,571 |
| Servier Pharmaceuticals LLC | $17,957 |
| Syndax Pharmaceuticals, Inc. | $17,705 |
| Pharmaessentia USA Corporation | $17,442 |
| Rigel Pharmaceuticals, Inc. | $14,098 |
| AbbVie Inc. | $9,095 |
| Compensation for services other than consulting (speaking, faculty) | $107,794 |
|---|---|
| Consulting Fee | $30,388 |
| Honoraria | $20,526 |
| Travel and Lodging | $10,666 |
| Speaking at a medical education program | $7,560 |
| Food and Beverage | $3,740 |
| Education | $89.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC Dec 5, 2025 | Consulting Fee Tibsovo · Oncology | $10,080 |
| Pharmaessentia USA Corporation Oct 13, 2025 | Consulting Fee BESREMI · Oncology | $8,710 |
| Genzyme Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $6,688 |
| Genzyme Corporation Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $5,618 |
| Genzyme Corporation Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $5,618 |
| Genzyme Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $5,618 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| AstraZeneca Pharmaceuticals LP May 8, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| Rigel Pharmaceuticals, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $5,148 |
| Rigel Pharmaceuticals, Inc. Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $5,148 |
All 113 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 22, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $238 |
| Servier Pharmaceuticals LLC Dec 18, 2025 | Speaking at a medical education program Tibsovo · Oncology | $1,260 |
| Pharmaessentia USA Corporation Dec 15, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $419 |
| Syndax Pharmaceuticals, Inc. Dec 12, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SAN ANTONIO, TX | $161 |
| Syndax Pharmaceuticals, Inc. Dec 12, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SAN ANTONIO, TX | $21.00 |
| Servier Pharmaceuticals LLC Dec 5, 2025 | Consulting Fee Tibsovo · Oncology | $10,080 |
| Syndax Pharmaceuticals, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $4,165 |
| Syndax Pharmaceuticals, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,678 |
| Syndax Pharmaceuticals, Inc. Nov 18, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SAN ANTONIO, TX · in-kind | $277 |
| Syndax Pharmaceuticals, Inc. Nov 18, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SAN ANTONIO, TX · in-kind | $235 |
| Servier Pharmaceuticals LLC Nov 11, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Las Vegas, NV | $222 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| Sanofi US Services Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) AYVAKIT · Gastroenterology | $583 |
| Servier Pharmaceuticals LLC Nov 10, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Las Vegas, NV | $60.97 |
| Syndax Pharmaceuticals, Inc. Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $893 |
| Genzyme Corporation Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $5,618 |
| Genzyme Corporation Oct 23, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Little Rock, AR · in-kind | $554 |
| Genzyme Corporation Oct 23, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Little Rock, AR · in-kind | $496 |
| Genzyme Corporation Oct 23, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Little Rock, AR · in-kind | $150 |
| Genzyme Corporation Oct 23, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Little Rock, AR | $21.00 |
| Genzyme Corporation Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $5,618 |
| Genzyme Corporation Oct 22, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Houston, TX · in-kind | $389 |
| Genzyme Corporation Oct 22, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Houston, TX · in-kind | $287 |
| Pharmaessentia USA Corporation Oct 22, 2025 | Travel and Lodging BESREMI · Oncology · travel to Tyler, TX | $152 |
| Genzyme Corporation Oct 22, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Houston, TX | $21.00 |
| Pharmaessentia USA Corporation Oct 22, 2025 | Travel and Lodging BESREMI · Oncology · travel to Tyler, TX | $10.05 |
| Incyte Corporation Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $1,650 |
| Incyte Corporation Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $1,100 |
| Syndax Pharmaceuticals, Inc. Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $4,165 |
| Genmab U.S., Inc. Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) Epkinly · Oncology | $2,375 |
| Pharmaessentia USA Corporation Oct 13, 2025 | Consulting Fee BESREMI · Oncology | $8,710 |
| Syndax Pharmaceuticals, Inc. Oct 7, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to TYLER, TX · in-kind | $943 |
| Pharmaessentia USA Corporation Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $4,690 |
| E.r. Squibb & Sons, L.l.c. Oct 3, 2025 | Consulting Fee | $455 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Houston, TX | $21.00 |
| AbbVie Inc. Sep 22, 2025 | Education IMBRUVICA · ONCOLOGY · in-kind | $89.99 |
| AstraZeneca Pharmaceuticals LP Sep 18, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Houston, TX · in-kind Company’s descriptionSpeaker Expenses | $728 |
| AstraZeneca Pharmaceuticals LP Sep 18, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Houston, TX · in-kind Company’s descriptionSpeaker Expenses | $449 |
| Rigel Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging REZLIDHIA · Acute Myeloid Leukemia · travel to Las Vegas, NV | $206 |
| Rigel Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging REZLIDHIA · Acute Myeloid Leukemia · travel to Las Vegas, NV | $185 |
| Genzyme Corporation Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $4,280 |
| Rigel Pharmaceuticals, Inc. Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $5,148 |
| AbbVie Inc. Aug 22, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,128 |
| Adaptive Biotechnologies Corporation Aug 21, 2025 | Consulting Fee clonoSEQ · Devices | $1,400 |
| Rigel Pharmaceuticals, Inc. Aug 21, 2025 | Travel and Lodging REZLIDHIA · Acute Myeloid Leukemia · travel to Las Vegas, NV · in-kind | $526 |
| Pharmaessentia USA Corporation Aug 18, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $1,340 |
| Rigel Pharmaceuticals, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $5,148 |
| Syndax Pharmaceuticals, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,678 |
| Servier Pharmaceuticals LLC Aug 15, 2025 | Speaking at a medical education program Tibsovo · Oncology | $1,260 |
| Sanofi US Services Inc. Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,166 |
| Genzyme Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $6,688 |
| Sanofi US Services Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) AYVAKIT · Gastroenterology | $1,166 |
| Genzyme Corporation Jul 31, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Gilbert, AZ · in-kind | $344 |
| Genzyme Corporation Jul 31, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Gilbert, AZ · in-kind | $234 |
| Genzyme Corporation Jul 31, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Gilbert, AZ · in-kind | $120 |
| Genzyme Corporation Jul 31, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Gilbert, AZ | $28.99 |
| Genzyme Corporation Jul 31, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Gilbert, AZ | $21.00 |
| Rigel Pharmaceuticals, Inc. Jul 30, 2025 | Travel and Lodging REZLIDHIA · Acute Myeloid Leukemia · travel to Houston, TX · in-kind | $676 |
| Rigel Pharmaceuticals, Inc. Jul 30, 2025 | Travel and Lodging REZLIDHIA · Acute Myeloid Leukemia · travel to Houston, TX · in-kind | $491 |
| Syndax Pharmaceuticals, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY Company’s descriptionBranded Speaker Training | $893 |
| AstraZeneca Pharmaceuticals LP Jul 25, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Grapevine, TX | $32.90 |
| AstraZeneca Pharmaceuticals LP Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $2,680 |
| Blueprint Medicines Corporation Jul 17, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,166 |
| Genzyme Corporation Jul 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,494 |
| Genzyme Corporation Jul 15, 2025 | Travel and Lodging travel to Grapevine, TX | $35.49 |
| Servier Pharmaceuticals LLC Jul 3, 2025 | Speaking at a medical education program Tibsovo · Oncology | $1,260 |
| Genzyme Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $5,618 |
| Incyte Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $1,650 |
| Genzyme Corporation Jul 1, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to San Antonio, TX · in-kind | $275 |
| Genzyme Corporation Jul 1, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to San Antonio, TX · in-kind | $235 |
| Genzyme Corporation Jul 1, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to San Antonio, TX | $21.00 |
| E.r. Squibb & Sons, L.l.c. Jun 23, 2025 | Consulting Fee | $455 |
| Rigel Pharmaceuticals, Inc. Jun 20, 2025 | Honoraria REZLIDHIA · Acute Myeloid Leukemia | $1,463 |
| Blueprint Medicines Corporation Jun 16, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,166 |
| Genzyme Corporation Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $1,070 |
| Incyte Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $1,650 |
| E.r. Squibb & Sons, L.l.c. Jun 11, 2025 | Consulting Fee | $2,013 |
| Blueprint Medicines Corporation Jun 2, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,166 |
| AstraZeneca Pharmaceuticals LP May 28, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Midlothian, TX | $44.31 |
| AstraZeneca Pharmaceuticals LP May 27, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $4,020 |
| Servier Pharmaceuticals LLC May 16, 2025 | Speaking at a medical education program Tibsovo · Oncology | $560 |
| Genzyme Corporation May 15, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $1,873 |
| AstraZeneca Pharmaceuticals LP May 8, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| Blueprint Medicines Corporation May 2, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $3,790 |
| Blueprint Medicines Corporation May 2, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $583 |
| Pharmaessentia USA Corporation Apr 30, 2025 | Consulting Fee BESREMI · Oncology | $335 |
| Incyte Corporation Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,200 |
| Servier Pharmaceuticals LLC Apr 25, 2025 | Speaking at a medical education program Tibsovo · Oncology | $1,260 |
| Blueprint Medicines Corporation Apr 17, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $583 |
| AbbVie Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $3,325 |
| Servier Pharmaceuticals LLC Apr 11, 2025 | Speaking at a medical education program Tibsovo · Oncology | $1,260 |
| Incyte Corporation Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $275 |
| Servier Pharmaceuticals LLC Apr 4, 2025 | Speaking at a medical education program Tibsovo · Oncology | $700 |
| Blueprint Medicines Corporation Apr 2, 2025 | Travel and Lodging AYVAKIT · Oncology / Rare Diseases · travel to Norman, OK · in-kind | $1,081 |
| AbbVie Inc. Mar 26, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to HOUSTON, TX · in-kind | $667 |
| AbbVie Inc. Mar 26, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to HOUSTON, TX · in-kind | $167 |
| AbbVie Inc. Mar 26, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to HOUSTON, TX · in-kind | $20.00 |
| Blueprint Medicines Corporation Mar 19, 2025 | Honoraria | $2,041 |
| AbbVie Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $1,425 |
| Blueprint Medicines Corporation Mar 14, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $3,276 |
| Blueprint Medicines Corporation Mar 14, 2025 | Travel and Lodging AYVAKIT · Oncology / Rare Diseases · travel to Grapevine, TX | $35.00 |
| Pharmaessentia USA Corporation Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $1,675 |
| AstraZeneca Pharmaceuticals LP Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $250 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $1,070 |
| AbbVie Inc. Feb 18, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,663 |
| AstraZeneca Pharmaceuticals LP Jan 28, 2025 | Consulting Fee | $1,675 |
| Lilly USA, LLC Jan 27, 2025 | Consulting Fee JAYPIRCA · Oncology | $2,000 |
| Blueprint Medicines Corporation Jan 24, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,008 |
| AbbVie Inc. Jan 24, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $238 |
| Blueprint Medicines Corporation Jan 9, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $3,276 |
| Blueprint Medicines Corporation Jan 9, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,008 |
| Blueprint Medicines Corporation Jan 9, 2025 | Travel and Lodging AYVAKIT · Oncology / Rare Diseases · travel to Plano, TX | $23.85 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $138,839 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma
Genentech, Inc. - A phase 1 study of SEACD70 in myeloid malignancies
Pfizer Inc. - A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications
Karyopharm Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.